RecruitingNCT06485271

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Sponsor

Changzhi People's Hospital Affiliated to Changzhi Medical College

Enrollment

504 participants

Start Date

Nov 1, 2023

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer RWS PD-1 Immunotherapy

Summary

The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria5

Age ≥18 years old, both male and female;
patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;
Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;
The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;
Voluntary enrollment; good compliance and willingness to cooperate with follow-up.

Exclusion Criteria4

Pregnant or lactating women;
Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);
Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);
Patients who, in the judgment of the investigator, are not suitable for inclusion.